Black Diamond Therapeutics, Inc. (BDTX) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
4.42
↓-33% vs avg
5yr avg: 6.63
30Y Low6.6·High6.6
P/FCF
3.21
↓-32% vs avg
5yr avg: 4.72
30Y Low4.7·High4.7
P/B Ratio
↑
0.85
↓-19% vs avg
5yr avg: 1.05
30Y Low0.6·High3.4
ROE
↑
22.9%
↓+151% vs avg
5yr avg: -45.2%
30Y Low-71%·High23%
Debt/EBITDA
0.75
+0% vs avg
5yr avg: 0.75
30Y Low0.7·High0.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BDTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Black Diamond Therapeutics, Inc. trades at 4.3x earnings, 32% below its 5-year average of 6.2x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 81%. On a free-cash-flow basis, the stock trades at 3.2x P/FCF, 32% below the 5-year average of 4.7x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $95M | $140M | $118M | $124M | $65M | $193M | $1.1B | — | — | — |
| Enterprise Value | $89M | $134M | $104M | $93M | $59M | $156M | $1.0B | — | — | — |
| P/E Ratio → | 4.26 | 6.23 | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.36 | 2.00 | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.85 | 1.25 | 1.41 | 1.06 | 0.56 | 0.98 | 3.43 | — | — | — |
| P/FCF | 3.21 | 4.72 | — | — | — | — | — | — | — | — |
| P/OCF | 3.21 | 4.72 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BDTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Black Diamond Therapeutics, Inc.'s enterprise value stands at 4.4x EBITDA, 33% below its 5-year average of 6.6x. The Healthcare sector median is 14.2x, placing the stock at a 69% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.91 | — | — | — | — | — | — | — | — |
| EV / EBITDA | 4.42 | 6.63 | — | — | — | — | — | — | — | — |
| EV / EBIT | 4.49 | 6.74 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 4.52 | — | — | — | — | — | — | — | — |
BDTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Black Diamond Therapeutics, Inc. earns an operating margin of 28.4%. ROE of 22.9% indicates solid capital efficiency. ROIC of 17.0% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.5% | 99.5% | — | — | — | — | — | — | — | — |
| Operating Margin | 28.4% | 28.4% | — | — | — | — | — | — | — | — |
| Net Profit Margin | 32.0% | 32.0% | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.9% | 22.9% | -69.7% | -70.9% | -58.5% | -49.9% | -51.6% | — | — | — |
| ROA | 16.8% | 16.8% | -49.6% | -52.4% | -45.1% | -43.5% | -27.6% | -33.6% | -29.8% | -57.4% |
| ROIC | 17.0% | 17.0% | -76.3% | -66.4% | -51.9% | -43.2% | -130.3% | — | — | — |
| ROCE | 17.3% | 17.3% | -65.4% | -61.8% | -50.9% | -47.0% | -29.7% | -8.8% | -32.4% | -71.1% |
BDTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Black Diamond Therapeutics, Inc. carries a Debt/EBITDA ratio of 0.7x, which is very conservative (77% below the sector average of 3.2x). The company holds a net cash position — cash of $21M exceeds total debt of $15M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.27 | 0.22 | 0.24 | 0.15 | 0.03 | — | — | — |
| Debt / EBITDA | 0.75 | 0.75 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.05 | -0.17 | -0.26 | -0.05 | -0.19 | -0.08 | — | — | — |
| Net Debt / EBITDA | -0.29 | -0.29 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -0.20 | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -67254.00 | — | — | -63.37 |
Net cash position: cash ($21M) exceeds total debt ($15M)
BDTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Black Diamond Therapeutics, Inc.'s current ratio of 8.42x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 6.82x to 8.42x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.42 | 8.42 | 4.92 | 6.82 | 8.37 | 9.12 | 22.48 | 32.02 | 20.07 | 3.55 |
| Quick Ratio | 8.42 | 8.42 | 4.92 | 6.82 | 8.37 | 9.12 | 22.48 | 32.02 | 20.07 | 3.55 |
| Cash Ratio | 8.18 | 8.18 | 4.79 | 6.69 | 8.05 | 8.87 | 22.16 | 31.80 | 20.06 | 3.53 |
| Asset Turnover | — | 0.49 | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
BDTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Black Diamond Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 23.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 23.5% | 16.0% | — | — | — | — | — | — | — | — |
| FCF Yield | 31.1% | 21.2% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $58M | $55M | $44M | $36M | $36M | $33M | $36M | $14M | $7M |
Peer Comparison
Compare BDTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BDTXYou | $95M | 4.3 | 4.4 | 3.2 | 99.5% | 28.4% | 22.9% | 17.0% | 0.7 |
 KYMR | $7B | -24.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 NUVL | $9B | -21.1 | — | — | — | — | -36.7% | -32.5% | — |
 AUPH | $2B | 8.0 | 18.5 | 15.6 | 88.5% | 37.1% | 59.9% | 16.6% | 0.7 |
 ERAS | $4B | -31.1 | — | — | — | — | -33.3% | -27.9% | — |
 ARVN | $495M | -6.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 MGNX | $263M | -3.5 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
 PRME | $583M | -2.4 | — | — | -58.1% | -4498.1% | -146.8% | -168.3% | — |
 CGEM | $924M | -4.0 | — | — | — | — | -44.0% | -43.5% | — |
 TYRA | $2B | -14.1 | — | — | — | — | -39.8% | -44.8% | — |
 RGEN | $7B | 153.5 | 54.7 | 79.3 | 47.1% | 8.1% | 2.4% | 2.2% | 5.0 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
BDTX — Frequently Asked Questions
Quick answers to the most common questions about buying BDTX stock.
What is Black Diamond Therapeutics, Inc.'s P/E ratio?
Black Diamond Therapeutics, Inc.'s current P/E ratio is 4.3x. The historical average is 6.2x.
What is Black Diamond Therapeutics, Inc.'s EV/EBITDA?
Black Diamond Therapeutics, Inc.'s current EV/EBITDA is 4.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.6x.
What is Black Diamond Therapeutics, Inc.'s ROE?
Black Diamond Therapeutics, Inc.'s return on equity (ROE) is 22.9%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -46.3%.
Is BDTX stock overvalued?
Based on historical data, Black Diamond Therapeutics, Inc. is trading at a P/E of 4.3x. Compare with industry peers and growth rates for a complete picture.
What are Black Diamond Therapeutics, Inc.'s profit margins?
Black Diamond Therapeutics, Inc. has 99.5% gross margin and 28.4% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Black Diamond Therapeutics, Inc. have?
Black Diamond Therapeutics, Inc.'s Debt/EBITDA ratio is 0.7x, indicating low leverage. A ratio below 2x is generally considered financially healthy.